ClinicalTrials.gg
Not yet recruitingNCT06956196Updated May 4, 2025

Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

A Phase 3 interventional study of Stapokibatrt and Placebo in Atopic Dermatitis, sponsored by Keymed Biosciences Co.Ltd. Not yet recruiting at 1 site in China. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2025-05-04.

Sponsored by Keymed Biosciences Co.Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing stapokibart in Dermatitis, Atopic — 2 open to participants now, 3 under way, 3 of them phase 3. stapokibart · Dermatitis, Atopic.

Planned enrollment
3rd of 12
240 · median 170
Started
2025
with 1 other
Phase 3
5 of 12
2 open now
Registered
11th of 12
by date
Lead sponsor
12 of 12
Keymed Biosciences Co.Ltd

Among the 12 studies testing stapokibart in Dermatitis, Atopic, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 3, and was the 11th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 12 studies testing stapokibart in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About stapokibart

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing stapokibart in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, Pharmacokinetics(PK), PharmacoDynamics(PD) and immunogenicity of Stapokibatrt in children with moderate-to-severe atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 2 and ≤ 11 years old.
  • Diagnosis of AD according to the American Academy of Dermatology Consensus (2014) Criteria.
  • With moderate-to-severe AD, and inadequate response to topical medications.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with Stapokibart
  • Treatment with dupilumab within 13 weeks prior to the baseline visit, or treatment with anti-IgE(Immunoglobulin E) monoclonal antibody,other biological agents within 5 half-lives prior to the baseline visit .
  • Treatment with /immunomodulatory drugs, ultraviolet therapy, or systemic traditional Chinese medicine for AD within 4 weeks prior to the baseline visit.
  • Treatment with a topical (TCS), topical calcineurin inhibitor (TCI) or topical Phosphodiesterase-4(PDE-4) inhibitor within 1 weeks prior to the baseline visit.
  • History of atopic keratoconjunctivitis invading cornea.
  • Acute attacks of Atopic Dermatitis within 4 weeks prior to the baseline visit.
  • Planned major surgical procedure during the patient's participation in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Stapokibatrt group

    Biological: Stapokibatrt

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • BiologicalStapokibatrt

    Stapokibatrt 1 or 2 ml,Subcutaneous injection(SC)

  • OtherPlacebo

    Placebo of matching volume,Subcutaneous injection(SC)

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving Eczema Area and Severity Index(EASI-75) at week 18

    The EASI is a composite index with scores ranging from 0 to 72. Four Atopic Dermatitis(AD) disease characteristics (erythema, edema/papulation, excoriation, lichenification) will each be assessed for severity by the investigator on a scale of "0" (none) through "3" (severe).

    Time frame: Up to week 18

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for May 2026, 12 months later.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 12 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
May 4, 2025
StartEst.
May 2025
Primary completionEst.
May 2026
CompletionEst.
Aug 2026
Last update
May 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06956196
Responsible party
Sponsor
First posted
May 4, 2025
Start date
May 2025 (estimated)
Primary completion
May 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
May 4, 2025

Study contacts

Qian Jia
Contact
qianjia@keymedbio.com
028-88610620
Lin Ma
principal investigator · Beijing Children's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion